Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 5 Odds ratio with 95% confidence intervals (CI) and corresponding p values for treatment effect on 30-day mortality among diabetic patients with acute coronary syndromes. Values to the left of 1.0 indicate survival benefit of platelet glycoprotein IIb/IIIa inhibition. GUSTO = Global Use of STrategies to Open occluded arteries in acute coronary syndromes trial; PARAGON = Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome Global Organization Network trial; PRISM-PLUS = Platelet Receptor inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms trial; PURSUIT = Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy trial. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non–ST-segment elevation acute coronary syndromes. Circulation 2001;104:2767–71. Reproduced with permission from Lippincott, Williams and Wilkins.
|
